AP
VRTX icon

Aspect Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Aspect Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Hold
21
– – ﹤0.01% 276
2026
Q1 		$9.38K Hold
21
– – ﹤0.01% 273
2025
Q4 		$9.52K Hold
21
– – ﹤0.01% 279
2025
Q3 		$8.22K Sell
21
-1
-5% -$418 ﹤0.01% 332
2025
Q2 		$9.79K Sell
22
-2
-8% -$922 ﹤0.01% 286
2025
Q1 		$11.6K Buy
24
+2
+9% +$932 0.01% 244
2024
Q4 		$8.86K Sell
22
-1
-4% -$464 0.01% 300
2024
Q3 		$10.7K Hold
23
– – 0.01% 261
2024
Q2 		$10.8K Sell
23
-7
-23% -$3.04K 0.01% 255
2024
Q1 		$12.5K Hold
30
– – 0.01% 247
2023
Q4 		$12.2K Buy
+30
New +$11.1K 0.01% 239

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Aspect Partners's VRTX Position: Q2 2026 in Review

Aspect Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 21 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #276.

Aspect Partners first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $12.5K in Q1 2024. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Aspect Partners held 21 shares of Vertex Pharmaceuticals worth $10.4K as of Q2 2026.
  • Aspect Partners left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #276 holding.
  • Aspect Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Aspect Partners's Vertex Pharmaceuticals position peaked at $12.5K in Q1 2024.
  • 296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.